SCYNEXIS Inc SCYX

Healthcare Biotechnology

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

NDAQ:SCYX - Post by User

SCYNEXIS Inc > Drug just got approved! :)

<< Previous

Bullboard Posts

Next >>

Comment by JonathanJSmithon Jun 02, 2021 3:58pm

84 Views

Post# 33312617

RE:RE:Drug just got approved! :)

Yeah, I wasn't expecting this kind of reaction either. The next few weeks will tell the tale; the approval information needs to be absorbed. Based on the CC today, I inferred that an EMEA partnership will be forthcoming shortly. As Tags put it: "stay tuned". :)

I haven't sold one share or option yet and don't intend to for the foreseeable future (unless something material happens....like Merck buying them out!).

Cheers and good luck if you're long,

JJ

<< Previous

Bullboard Posts

Next >>

Elon Musk sued by SEC over Twitter stock purchases